Copd Exacerbation clinical trials

Explore recruiting copd exacerbation clinical trials.

Recruiting copd exacerbation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Copd Exacerbation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.

Hungary

Therapeutic use (Phase IV) EU CTIS Study details

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

Sweden, Romania, Spain, Italy, Germany, Poland +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients in the intensive care unit: a multicentre randomized controlled trial

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A two-center, randomized, double-blind, placebo-controlled study of intravenous plasma-purified alpha-1 antitrypsin for hospitalized patients with COPD exacerbations (AECOPD study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Parallel Group, Multi-Center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Hungary, Norway, Spain, Denmark, Slovakia, Bulgaria +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Romania, Lithuania, Hungary, Spain, Bulgaria, Ireland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Copd Exacerbation trials by city

Copd Exacerbation in Toronto Copd Exacerbation in Vancouver Copd Exacerbation in Montreal Copd Exacerbation in Calgary Copd Exacerbation in Edmonton Copd Exacerbation in Ottawa Copd Exacerbation in Winnipeg Copd Exacerbation in Quebec City Copd Exacerbation in Hamilton Copd Exacerbation in Kitchener Copd Exacerbation in London Copd Exacerbation in Halifax Copd Exacerbation in New York Copd Exacerbation in Los Angeles Copd Exacerbation in Chicago Copd Exacerbation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease